Best Medicare Advantage Plan for GLP-1 Coverage: What Actually Decides It

Affiliate disclosure: The RX Index may earn a commission from some provider links on this page, and those links are labeled. Links to Medicare, CMS, the Medicare Plan Finder, and SHIP counseling are not affiliate links and never will be. Nothing we earn changes what we tell you about Medicare coverage. The Medicare and government-help paths we put first on this page pay us nothing.

By The RX Index Research Team · Last verified: August 18, 2026

There is no single best Medicare Advantage plan for GLP-1 coverage. If you want a GLP-1 for weight management alone and you qualify, a federal program called the Medicare GLP-1 Bridge can provide one eligible 28- or 30-day supply for $50. Most coordinated-care Medicare Advantage plans with drug coverage meet the plan-type rule. Your exact plan's formulary decides the answer only when the prescription goes through regular Part D.

That flips the usual advice on its head.

Because here's the thing almost nobody tells you: the most expensive mistake on this page isn't picking the wrong insurance company. It's switching plans you never needed to switch — and losing your doctor, your pharmacy, or your coverage for three other medications to get something you already had.

We went through CMS's own Medicare GLP-1 Bridge documents line by line on August 18, 2026. Below is what actually controls your GLP-1 access, in the order it controls it — plus the one plan choice that can quietly cost you the $50 program, and what changes on January 1, 2027.

The one-screen answer

A past heart attack, stroke, or symptomatic peripheral artery disease does not by itself block the Bridge. At a starting BMI of 27 or higher, one of those conditions can help you qualify when the prescription is solely for weight management. If Wegovy is prescribed in any part to reduce major cardiovascular events, the prescription routes to Part D.

Two lanes. Same drugs. Completely different rulebooks. Mix them together and you can make the wrong plan decision.

This page is for you if

• You're choosing or changing a Medicare Advantage plan for 2027.
• You want Wegovy, Zepbound, Foundayo, Ozempic, Mounjaro, or another GLP-1.
• You're not sure whether your plan's drug list or the federal program controls your access.
• You heard Humana runs the $50 program and wondered if that means you need a Humana plan.
• Your plan is ending in 2027 and you're being forced to shop anyway.

This is not the right page if

• You just want to know if your current plan covers one drug. → Does Medicare Advantage cover Zepbound?
• You only need the medical eligibility rules for the $50 program. → Medicare GLP-1 Bridge Program
• You have employer, marketplace, or federal employee insurance, not Medicare. → How to get insurance to cover a GLP-1

We'd rather send you to the right page than keep you on the wrong one.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

A note before you compare anything: The right GLP-1 treatment path isn't the same for everyone — it depends on your state, your Medicare plan type and formulary, whether you want an FDA-approved medication or are considering a compounded drug that is not FDA-approved, your preferred treatment path (injection or oral), and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized match with source-verified pricing before you choose.

What is the best Medicare Advantage plan for GLP-1 coverage?

Answer: No single Medicare Advantage plan is best for every GLP-1 user. For weight-loss-only prescriptions covered by the Medicare GLP-1 Bridge, any eligible Medicare Advantage plan with drug coverage can satisfy the coverage requirement, because the Bridge runs outside your plan and insurers do not opt in. For type 2 diabetes, obstructive sleep apnea, MASH, or cardiovascular risk reduction, the best plan is the specific local plan that covers your exact drug at the lowest total annual cost while keeping your doctors and other prescriptions intact.

Let's slow down on two words: plan and formulary.

Your plan is the specific product you're enrolled in — not just "Aetna," but the exact local HMO, PPO, or other plan named on your card, with its own contract ID and plan ID. Medicare Advantage plans are local. Two people with the same company logo on their card can have completely different drug coverage.

Your formulary is your plan's list of covered drugs. Every plan has one. They are not the same from plan to plan, and they reset every January 1.

Now here's what most pages get wrong.

Your GLP-1 goes through one of five doors

The reason written on your prescription — not the brand name on the box — decides which door you're in. We built this table by reading CMS's Bridge documents for beneficiaries, pharmacies, prescribers, and Part D plans, then matching each one to the FDA-approved use it corresponds to.

MASH stands for metabolic dysfunction-associated steatohepatitis, a liver condition previously called NASH. OSA is obstructive sleep apnea, where your airway closes during sleep.

Doors 2, 4, and 5 close Door 1. Door 3 depends on why Wegovy is being prescribed. This is the single most misunderstood rule in the whole system, so read it twice: type 2 diabetes, moderate-to-severe sleep apnea, and qualifying MASH make the prescription a Part D matter. A prior heart attack, stroke, or symptomatic peripheral artery disease does not automatically close the Bridge. But if Wegovy is prescribed in any part to reduce major cardiovascular events, that prescription must go to Part D — even when your plan doesn't actually have the drug on its list.

Sit with that. You can be told "your plan doesn't cover this" and still be locked out of the $50 program, on the same day, for the opposite reason. Two doors, both shut, same person.

That's not a loophole to exploit. It's a routing problem to solve — and it's solvable if you know which door you're standing in before your doctor writes anything.

Do you qualify for the $50 Bridge? The short version

You need to be 18 or older, in an eligible Medicare drug plan, prescribed a covered drug solely to reduce excess weight and maintain weight reduction, and using ongoing lifestyle changes that include structured nutrition and physical activity when activity is clinically appropriate. You also need to meet one of these three sets of numbers — measured at the time you started GLP-1 treatment, not today:

One detail worth real money: CMS uses your BMI when you started the medication, not your BMI now. If you already lost weight on a GLP-1 and dropped below the threshold, your prescriber can still attest to your starting number. Do not rule yourself out by looking only at today's BMI.

Full criteria, forms, and the application steps live on our Medicare GLP-1 Bridge Program guide — we're not going to repeat all of it here, because your question is about picking a plan.

### Not sure which of the five doors is yours? That one answer changes everything else on this page — your cost, whether your plan matters, and who approves the prescription. → Check your GLP-1 path in about two minutes Use the result to separate the Bridge, Part D, and cash-pay paths before you compare plans.

Does every Medicare Advantage plan qualify for the $50 GLP-1 Bridge?

Answer: No. To use the Medicare GLP-1 Bridge you must be enrolled in a standalone Part D drug plan or a Medicare Advantage coordinated care plan with drug coverage — an HMO, HMO-POS, local PPO, or regional PPO. Special Needs Plans, employer or union retiree plans, and LI NET also qualify. Private fee-for-service plans, Cost Plans, Medical Savings Account plans, PACE, health care prepayment plans, fallback plans, and religious fraternal benefit plans do not qualify by themselves. Some of those members can become eligible through a separate standalone Part D plan, but the enrollment rules are not the same for every plan type.

This is the one place where your Medicare Advantage choice genuinely can cost you the $50 program. Here it is as a shopping rule, based on CMS's eligible-plan list and Medicare's plan-type rules:

A coordinated care plan is a plan with a provider network — an HMO or PPO. A Special Needs Plan serves people with specific situations, like having both Medicare and Medicaid. LI NET is temporary drug coverage for certain people who qualify for Extra Help and do not yet have another Part D plan.

⚠️ The warning that could cost you your whole health plan

If you're in a Medicare Advantage HMO, HMO-POS, or PPO and you sign up for a standalone Part D drug plan to "add" Bridge eligibility, Medicare will normally disenroll you from your Medicare Advantage plan and put you back on Original Medicare.

Read that again before you touch anything.

You wouldn't just be adding drug coverage. You'd be giving up your medical plan, your network, your medical out-of-pocket maximum, and every extra benefit you have — probably without meaning to.

One more risk: going back to Original Medicare does not always give you a guaranteed right to buy a Medigap policy. Outside certain protected situations, an insurer may charge more or deny your application. Some states give extra rights. Check this before you leave the plan.

The exceptions are narrow: people in a PFFS plan without drug coverage, a Medical Savings Account plan, and some Medicare Cost Plans can add a standalone drug plan without automatically losing the health plan they already have.

If you're in a Medicare Advantage HMO, HMO-POS, or PPO with no drug coverage and you want a GLP-1, the honest move is to compare Medicare Advantage plans that include drug coverage during an enrollment window — not to bolt a drug plan onto what you have.

If your coverage comes through a former employer or union, call the benefits administrator before you enroll in anything. A change can affect medical, drug, and retiree coverage together.

How to find your exact plan type in two minutes

1. Look at your plan's Summary of Benefits or Evidence of Coverage. The plan type is in the title.
2. Look at the plan name on your card. It usually says HMO, HMO-POS, PPO, PFFS, SNP, Cost, or MSA.
3. Still unsure? Call 1-800-MEDICARE and ask two questions: "What type of plan am I in?" and "Does it include Part D drug coverage, or am I enrolled in a separate Part D plan?"

Write both answers down. Everything else on this page depends on them.

Is Humana the best Medicare Advantage plan because Humana runs the $50 program?

Answer: No. CMS chose Humana as the national central processor for the Medicare GLP-1 Bridge, meaning Humana handles prior authorizations, claims, and payments to pharmacies for the whole country. That is an administrative contract, not a coverage advantage. Being in a Humana plan does not make a Bridge request more likely to be approved.

We're calling this out because readers keep asking it, and switching for this reason can be expensive.

CMS picked Humana because Humana already runs LI NET, a small national Medicare drug program with the exact plumbing this needed. Humana processes Bridge claims for eligible people in Aetna, UnitedHealthcare, Wellcare, Kaiser, and standalone drug plans. Your card doesn't have to say Humana for Humana's system to approve your prescription.

What that means for you: switching to a Humana Medicare Advantage plan to improve your odds of $50 GLP-1 coverage would gain you nothing on the Bridge, while potentially costing you your current doctors and your coverage for other medications.

There's a wrinkle worth knowing this year: Humana told investors on its July 29, 2026 earnings call that its targeted 2027 Medicare Advantage plan exits will affect about 600,000 members. Humana also said it will try to move a significant share of those members into other Humana plans. If your current plan is changing or ending, your Annual Notice of Change will arrive in September and tell you what happens next.

Which brings us to the question most of you actually came here to answer.

Should you switch Medicare Advantage plans just to get a GLP-1?

Answer: Usually not, if your prescription goes through the Medicare GLP-1 Bridge and your current plan is an eligible type — because switching cannot buy you better Bridge access. Switching can be worth it when your prescription goes through regular Part D and a different local plan covers your exact drug at a meaningfully lower total cost, but only after you check your doctors, your pharmacy, and every other medication you take.

Here's the honest version.

If you're in Door 1 (weight management only) and your plan is an eligible type, switching plans will not lower the $50 or change the Bridge approval rules. The Bridge doesn't look at your insurance company. It looks at your plan type, the purpose of the prescription, the clinical criteria, and your BMI when treatment started.

If your prescription goes through regular Part D, your plan is the whole ballgame. Two plans in the same ZIP code can put the same drug on different tiers, require different prior authorizations, or use different step-therapy rules. That gap can be expensive. Shop hard.

Seven questions to answer before you change anything

Answer these in order. If you get a clear "no reason to switch" in the first two, you can stop and save yourself a month of stress.

1. Which door is my prescription in? Weight loss only, or a Part D-covered condition?
2. Is my current plan an eligible Bridge type? (Use the table above.)
3. If my prescription goes through Part D: does another local plan actually list my exact drug and form?
4. Are my doctors and hospitals in that plan's network?
5. What happens to my other prescriptions on that plan?
6. Is my pharmacy in the new plan's preferred network?
7. Am I even in an enrollment window right now?

Reasons not to switch

• Your Medicare Advantage carrier does not decide Bridge requests. Humana's central processor handles eligible Bridge requests nationwide.
• Your other medications could get more expensive on the new plan's list.
• Networks change. Your cardiologist or endocrinologist may not be in the new one.
• The new plan might be an ineligible type — and you'd be worse off than you started.
• New plans can bring new referral rules, new authorizations, and new pharmacy restrictions.

When a switch genuinely makes sense

• Your prescription belongs in regular Part D and another local plan covers the exact drug and form better.
• Your other drugs are also covered well on that plan.
• Your doctors and hospitals are in network.
• Your total annual cost — premium plus deductible plus copays — is lower.
• Your plan is being discontinued for 2027 and you have to move anyway.

Your enrollment windows

Two dates to put on your calendar right now: September 30, 2026 — your plan must send your Annual Notice of Change by then, explaining major 2027 changes to costs and coverage. And October 1, 2026 — when 2027 plan comparison information becomes available in the Medicare Plan Finder.

Read the Annual Notice of Change the day it arrives. Most people throw it away. Formularies reset for the new plan year on January 1, and a plan that worked beautifully this year can quietly stop covering your drug next year. Then check the plan directory and call each doctor's office, because the notice does not replace a doctor-by-doctor network check.

### Before you give up a plan that's working A GLP-1 is only one line in the decision. A specialist, pharmacy, or another prescription can erase the savings from a switch. → Run the free Find My GLP-1 Path tool Then write down your answers to the seven questions above and decide with your eyes open.

When does your Medicare Advantage formulary actually matter?

Answer: Your formulary matters when the GLP-1 is prescribed for a condition regular Part D can cover — type 2 diabetes, moderate-to-severe obstructive sleep apnea, qualifying MASH, or cardiovascular risk reduction. It does not control access when the drug is furnished through the Medicare GLP-1 Bridge for eligible weight management. The same medication can follow completely different rules depending on why it was prescribed.

This is where careful shopping pays off, so let's go door by door.

Type 2 diabetes

Ozempic, Mounjaro, Rybelsus, Trulicity, and Victoza can all be covered under Part D for type 2 diabetes. But "can be" is doing heavy lifting. A plan may cover some and leave others off its list. It may also require prior authorization, step therapy, or a quantity limit.

Compare each drug separately in Plan Finder. Don't assume a plan that covers Ozempic also covers Mounjaro.

Zepbound for sleep apnea

Zepbound was approved by the FDA in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. That created a real Part D path.

But this is also a trap. If your prescription is for sleep apnea, you cannot use the $50 Bridge — even if your plan doesn't cover Zepbound at all. Your next step is your plan's coverage determination or formulary exception process, not the Bridge.

A plan's approval rules may ask for records showing moderate-to-severe OSA and obesity. Read the exact prior-authorization criteria instead of assuming the FDA approval alone guarantees payment.

Wegovy for heart-risk reduction

Wegovy injection and tablets are approved to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease who are overweight or have obesity.

Here's the subtle part, and it's the most decision-relevant sentence on this page: a prior heart attack, stroke, or symptomatic peripheral artery disease can also qualify you for the Bridge at BMI 27 or higher.

So which is it?

The prescriber's stated purpose decides. If Wegovy is being prescribed in any part to reduce major cardiovascular events, that prescription goes to Part D. If it is prescribed solely to reduce excess weight and maintain weight reduction, it can go to the Bridge — even in someone with that same history — if every other Bridge rule is met.

This isn't a coding game and we're not suggesting anyone misstate anything. It's a real clinical distinction that determines which system pays. It deserves a conversation with your doctor before the prescription is written, not after it's denied.

MASH

A qualifying noncirrhotic MASH prescription goes to Part D. Not the Bridge. The FDA-approved MASH product is Wegovy injection, not the tablets, for adults with moderate-to-advanced F2–F3 liver fibrosis.

"It's not on my formulary, so I'll just use the Bridge" — no

This is the most expensive assumption we found in this research.

CMS is explicit: if your prescription is for a use Part D could cover, you're not Bridge-eligible regardless of whether that drug is on your plan's list. Not being covered doesn't move you to the other lane. It just means you're in the first lane and denied.

What actually helps in that spot is your plan's formulary exception process — a formal request asking the plan to cover a drug that isn't on its list. That has real appeal rights behind it. We walk through it in how to appeal a GLP-1 denial.

The plan that "covers weight loss" may be the worst plan you can pick

Answer: Some Part D plans offer drugs used only for weight loss as a supplemental benefit under what Medicare calls enhanced alternative coverage. That is not the same as basic Part D. The extra benefit may be funded through added premium and, in Medicare Advantage drug plans, rebate dollars. Spending on the excluded weight-loss use does not count toward the basic Part D out-of-pocket threshold. A GLP-1 filled through a plan's supplemental benefit in 2026 also makes you ineligible for the Bridge for the rest of 2026.

We almost didn't include this section. Then we realized it's the single most likely way a careful reader could talk themselves into a bad plan.

Here's how it works. Basic Part D is barred by law from covering drugs when they are used only for weight loss. But an enhanced plan may add supplemental coverage for a drug that basic Part D excludes.

Sounds like exactly what you're looking for. Four problems:

1. The extra benefit may raise what you pay for the plan. For a standalone drug plan, the part of the bid tied to supplemental drug benefits raises the beneficiary premium. A Medicare Advantage drug plan may also use rebate dollars to help fund it.
2. It doesn't count toward your basic Part D cap. Money paid for an excluded weight-loss use does not move you toward the $2,400 Part D out-of-pocket threshold in 2027.
3. The appeal is narrower than many people expect. You can ask the plan for a coverage determination and appeal whether it delivered a supplemental benefit it promised. But an appeal cannot turn a weight-loss-only use into basic Part D coverage, force the spending into TrOOP, or create a benefit the plan never offered.
4. A 2026 supplemental fill closes the $50 door for 2026. CMS says a GLP-1 paid through supplemental Part D coverage counts in the Bridge's 2026 lookback. CMS had not set the 2027 lookback period as of August 18, 2026.

So in 2026, a plan advertising GLP-1 weight-loss coverage could cost more, give you less out-of-pocket protection, and lock you out of a $50 program you otherwise would have qualified for. For 2027, check the lookback rule again before you use the supplemental benefit.

Ask this exact question before you enroll: "Is this drug covered as basic Part D for my diagnosis, or only as a supplemental excluded-drug benefit?" Write down the answer and where it appears in the Evidence of Coverage.

When an enhanced plan can still be worth it: if your prescription is for a Part D-covered use and the plan covers your exact drug well, the plan may be genuinely excellent. Enhanced is not a red flag. Supplemental coverage of an excluded weight-loss use is the specific thing to inspect hard.

How do you compare Medicare Advantage plans for a GLP-1? (the 20-minute version)

Answer: Compare specific local plans in your ZIP code using the Medicare Plan Finder, not national company names. Enter every medication you take by exact brand, form, dose, and quantity; confirm your doctors and pharmacy are in network; and compare estimated total annual cost rather than monthly premium. Free, insurer-independent help is available through your State Health Insurance Assistance Program.

The Plan Finder is free, government-run, and does not sell you a plan. It's the right tool. But it can hand you the wrong comparison if you feed it a fuzzy drug name.

Step 1 — Enter your ZIP code

Medicare Advantage plans are sold county by county. A "best plan" list without your location is decoration.

Step 2 — Type the exact product, not the brand

This is the step that separates a useful comparison from a useless one. Plans treat different forms of the same drug differently.

That last row surprises people. Plan Finder's formulary result does not show Bridge access because the Bridge sits outside Part D. If you're in Door 1, a plan may show your drug as "not covered" under Part D and still meet the plan-type rule for a Bridge fill.

Step 3 — Add every other medication

Blood pressure pills. Cholesterol. Thyroid. Inhalers. All of it, with the exact dose, form, and monthly quantity. A plan that's great for your GLP-1 and terrible for your other four drugs is a bad plan.

Step 4 — Write down four things per plan

For your GLP-1 and every other drug:

• Tier (lower usually means cheaper)
• Prior authorization — yes or no
• Step therapy — yes or no
• Quantity limit — yes or no

Step 5 — Check the network

Primary doctor. Cardiologist. Endocrinologist. Sleep specialist. Obesity medicine clinician if you have one. Hospitals. And your pharmacy — preferred-pharmacy status can change what you pay. Check the plan directory, then call each office and pharmacy to confirm.

Step 6 — Compare total annual cost, not premium

Plan Finder estimates annual drug costs for you. Use that estimate. The lowest-premium plan can be the most expensive plan once deductibles, drug tiers, and medical copays are counted.

Do not add the drug deductible again if Plan Finder's annual drug-cost estimate already includes it. Compare: premium × 12, Plan Finder's estimated drug cost, expected medical copays, and the plan's maximum out-of-pocket limit for medical care.

Step 7 — Get free human help

SHIP — the State Health Insurance Assistance Program — gives free, one-on-one Medicare counseling and is not connected to any insurance company. SHIP counselors do not earn a commission on your enrollment. An insurance agent may.

We are telling you to call SHIP before you call anyone selling a plan, including anyone who found this page. That's not us being noble. It's that a SHIP counselor with your ZIP code and medication list can resolve details a national article cannot, and we'd rather be the page that got you to the right answer than the page that pretended to be it.

### Do this before you open Plan Finder First identify whether your prescription belongs in the Bridge or Part D. Then Plan Finder becomes a plan comparison instead of a search for coverage that may not appear there. → Run the free Find My GLP-1 Path tool It takes about two minutes. Bring the result, your full medication list, and your doctor list to Plan Finder or SHIP.

What will a GLP-1 actually cost you on Medicare?

Answer: Through the Medicare GLP-1 Bridge, a qualifying fill costs a flat $50 for each 28- or 30-day supply, regardless of dose. The $50 does not count toward your Part D deductible or out-of-pocket cap, Extra Help does not reduce it, and manufacturer coupons cannot be applied. Through regular Part D, costs vary by plan, with a $700 standard deductible and a $2,400 out-of-pocket cap in 2027.

Two very different cost structures. Here they are side by side.

That "no" on counting toward the cap deserves a second look. Once your qualifying out-of-pocket spending reaches $2,400 in 2027, you pay $0 for covered Part D drugs for the rest of the year. Bridge spending never gets you there. So if you take other expensive medications, $50 a month for twelve months is $600 that does nothing to move you toward that protection.

For an eligible weight-management fill, $50 is hard to beat. Just don't assume "cheapest per month" means "cheapest per year" across your whole prescription list.

Extra Help is worth checking first

Extra Help — also called the Low-Income Subsidy — can substantially cut your Part D premium, deductible, and copays if your income and resources qualify. It won't touch the $50 Bridge copay. But if your prescription goes through regular Part D, it can change your entire cost picture. Apply through Social Security. It's free.

What changes on January 1, 2027?

Answer: Medicare's negotiated prices for selected semaglutide products — Ozempic, Rybelsus, and Wegovy — take effect January 1, 2027. The often-quoted $274 figure is a standardized 30-day price, not a universal package price and not your copay. Actual maximum fair prices vary by product, package, and NDC. Part D plans must include the selected drug for uses that basic Part D can cover. This does not turn weight-loss-only Wegovy into a basic Part D benefit or replace the $50 Bridge. Tirzepatide products, Mounjaro and Zepbound, were not selected for 2027 negotiation.

We think this is the most important thing on this page that nobody else is explaining clearly to Medicare shoppers, so let's be precise about it.

Under the Inflation Reduction Act, Medicare negotiated prices for a second group of 15 selected drugs. CMS treats Ozempic, Rybelsus, and Wegovy as one selected drug because they share semaglutide as the active ingredient. CMS's headline standardized price is about $274 for a 30-day equivalent, about 71% below the listed $959 comparison price. It starts January 1, 2027 — the same day your new plan does.

The $274 headline is not the price of every package

CMS's published examples show why the distinction matters:

Those are underlying Medicare prices for the listed packages. Your pharmacy cost still depends on whether the use is covered, your plan's tier and rules, your deductible, and where you are in the benefit year.

Two consequences change how you shop:

Plain English: for 2027, someone using semaglutide for a Part D-covered purpose has stronger formulary protection than someone who needs tirzepatide. But neither mandatory formulary placement nor the $274 headline tells you what you will pay at the counter.

One more time so you're not disappointed: a 71% reduction in the underlying standardized price does not mean a 71% smaller copay. It also does not move a weight-loss-only Wegovy prescription from the Bridge into basic Part D.

How do your doctor and pharmacy get the claim to the right place?

Answer: For a Medicare GLP-1 Bridge request, the prescriber sends the prescription to the pharmacy first. The pharmacy submits the claim to the Bridge's dedicated processing route, which creates the patient's record and triggers the prior authorization request back to the prescriber. A denial from your Part D plan is not required first, and submitting the authorization before the pharmacy claim produces a "patient not found" error.

We're including this because a "patient not found" message is a sequencing problem, not a medical denial. The rules may be right. The steps just happened in the wrong order.

The correct order:

1. Your prescriber decides a covered Bridge drug may be appropriate for you.
2. Your prescriber sends the prescription to the pharmacy.
3. The pharmacy submits the claim to the Bridge's dedicated processing route.
4. That claim creates your record in the Bridge system and triggers the prior authorization process.
5. The pharmacy sends the authorization request to your prescriber, usually within 24–72 hours.
6. Your prescriber completes and submits it electronically or by fax.
7. You and your prescriber get a decision — CMS says within 72 hours after the prior authorization is submitted.
8. The pharmacy runs the claim again, and you pay $50.

The two rules that trip everyone up

You do not need a denial from your Part D plan first. Your prescriber can direct a potentially eligible prescription straight to the Bridge route.

But the pharmacy claim does have to come first. The prior authorization can't attach to a patient the system hasn't seen yet. If your doctor's office submits the paperwork before the pharmacy has run the claim, expect a "patient not found" rejection — and expect it to look like a coverage denial when it isn't.

For your pharmacist

If your pharmacy hasn't processed one of these yet, these are the routing details CMS published:

• BIN: 028918
• PCN: MEDDGLP1BR
• Electronic claims only — no paper claims, no member reimbursement after the fact
• Pharmacy Help Desk: 844-673-0910

Print that. Hand it over.

If the prescriber's office needs help with the prior authorization, the Medicare GLP-1 Bridge Call Center is 855-273-0102, Monday through Friday, 8 a.m. to 7 p.m. Eastern.

One approval covers you through 2027

Once approved, your Bridge authorization is good through December 31, 2027. Refills don't need new paperwork, and neither do dose changes. The one thing that requires a new authorization is switching from one covered Bridge drug to another — say, moving from Wegovy to the Zepbound KwikPen.

That approval does not override a later eligibility change. A Part D-paid GLP-1 fill or a move into an ineligible plan type can stop later Bridge refills.

What if the GLP-1 gets denied?

Answer: Identify who issued the denial before doing anything else. A Bridge rejection, a Part D formulary denial, an ineligible-plan-type rejection, a wrong-drug-form rejection, and a pharmacy routing error each require a different fix. "File an appeal" is only the right answer for one of them.

Two different systems, two different fixes.

Bridge denials don't go through the Part D appeal process. There's no formal Bridge appeal. Your prescriber can resubmit when information was wrong or when there is new information to add. Beneficiary questions go to 1-800-MEDICARE. Prescribers can call 855-273-0102. Your Medicare Advantage carrier does not decide the Bridge request.

Part D denials have real teeth behind them: coverage determination, then formulary exception, then redetermination, then further levels of appeal. Don't confuse the two. We cover the Part D side in how to appeal a GLP-1 denial.

One more thing worth knowing about 2026

If you filled any of these nine drugs through your Part D plan during 2026, you're locked out of the Bridge for 2026: Zepbound, Mounjaro, Foundayo, Rybelsus, Ozempic, Wegovy, Saxenda, Victoza, or Trulicity.

That catches people off guard. Someone taking Trulicity for diabetes in March who wants Wegovy for weight loss in October is locked out — even though those are completely different prescriptions for completely different reasons.

And here's the live question for anyone shopping right now: CMS has said it hasn't yet decided what lookback period will apply in 2027. So we can't tell you today whether a 2026 fill will still block you in January. Anyone who tells you confidently either way is guessing. We're checking that page weekly and will update this section the day it changes.

### Your plan may not be the problem A denial message can be a routing error, a wrong drug form, a Part D decision, or a true Bridge rejection. The fix starts with naming the system that issued it. → Open the Medicare GLP-1 Bridge step-by-step guide Use the sequence and processing details above when you speak with the pharmacy and prescriber.

Is Humana, Aetna, UnitedHealthcare, Wellcare, or Kaiser best for GLP-1 coverage?

Answer: No national carrier can be named the best Medicare Advantage plan for GLP-1 coverage. Medicare Advantage plans are sold county by county with different formularies, tiers, and networks under the same company name. Humana's role as the Bridge's central processor gives Humana plans no coverage advantage, and for Part D-covered indications the right answer depends on the specific plan available at your address.

We could write a neat "top 5 Medicare Advantage plans for GLP-1s" list. It would also be wrong for most of the people who read it, and we'd deserve whatever happened next.

Here's why company-level rankings fail here:

• Same logo, different plans. One company can offer several Medicare Advantage plans in your county with different drug lists.
• Networks are local. A plan that's excellent in Phoenix may not include your hospital in Tucson.
• Your GLP-1 is one line item. A plan that wins on Ozempic and loses on your other four drugs is a losing plan.
• The Bridge isn't a carrier competition. Your Medicare Advantage carrier does not approve the request; Humana serves as the central processor for eligible Bridge requests nationwide.

What to record instead

When you compare, write down these six things for each plan. This is what turns "I think Aetna is better" into an actual comparison:

1. Company name
2. Plan name
3. Contract ID and Plan ID — the identifiers shown in Plan Finder and your plan documents
4. Your county
5. Plan type (HMO, PPO, SNP, PFFS)
6. Whether it includes drug coverage

Already have one of these plans and want the carrier-specific rules? We keep verified pages separate: Humana · Aetna · Compare all local plans in Medicare Plan Finder

What people are actually asking

We read Medicare forums to understand how people describe this problem in their own words. These aren't coverage advice and they aren't customer reviews — they're the questions real people are stuck on right now.

From an r/medicare community discussion about the GLP-1 Bridge:

"Does anyone know if Wellcare will qualify for Glp-1?"

"Medicare is confusing enough without this monkey wrench thrown in!"

Those two questions show the real wrong turn: people ask whether a company like Wellcare "qualifies" before checking the exact plan type and whether the prescription belongs in the Bridge or Part D.

That's the trap in this whole system: being covered and being affordable are not the same thing, and a Part D-covered diagnosis can send the prescription to a more expensive route than the $50 Bridge.

These comments illustrate common questions and frustrations. They are not evidence of what your coverage will do, and they are not medical or insurance advice.

What if neither the Bridge nor your plan solves it?

Answer: The next step depends on why coverage failed. A Part D-covered prescription may support a coverage determination, formulary exception, or appeal. An ineligible plan type calls for enrollment counseling. Someone with no workable Medicare path may compare FDA-approved cash/self-pay options — which are not Medicare-covered and are not equivalent to the $50 Bridge.

Let's be straight about the order here, because the Medicare paths come first and we don't earn a dollar on them.

1. The $50 Bridge, if you qualify for a weight-management fill. It is the first path to check. We earn nothing. 2. Part D coverage through a well-chosen plan, if the prescription is for a covered use. We earn nothing. 3. Extra Help, if your income and resources qualify. We earn nothing. 4. Manufacturer cash/self-pay programs. No insurance claim. We earn nothing. 5. Cash-pay telehealth. The only rung on this list where a link may pay us.

That order isn't modesty. It's the order to check. A membership fee can make telehealth cost more than the same manufacturer cash price.

Manufacturer cash programs are different from copay cards

Manufacturer copay savings cards generally exclude people enrolled in Medicare or another federal health program. A true cash/self-pay program is different because the prescription is not submitted to Medicare.

Novo Nordisk's current NovoCare Pharmacy terms say people with government-funded insurance may self-pay for Wegovy, but they cannot submit the purchase to any insurer or seek reimbursement. Ro's current page says people with Medicare, a Medicare supplement plan, or TRICARE may qualify for certain cash-pay treatments through Ro Body.

Provider-stated cash terms verified August 18, 2026

These are provider-stated terms, not prices we control. We checked them on August 18, 2026. Dose, new-patient rules, state availability, prescription approval, and program terms can change.

We also update our GLP-1 price and access tracker with current channels and terms.

Who cash-pay telehealth is actually for

Not most of you. Specifically, it's for someone who:

• Has ruled out the Bridge because they do not qualify, had a blocking 2026 Part D GLP-1 fill, or cannot use an eligible plan type right now, and
• Does not have an affordable Part D path for the prescription, and
• Wants an FDA-approved medication now and accepts that the cash purchase will not count toward Medicare's deductible or out-of-pocket threshold.

If that's not you, skip this section. Seriously — go back up to the Plan Check and finish your comparison instead. You'll probably save money.

If it is you, here's the honest picture.

Our damaging admission, because you should have it before the link, not after: Ro does not process the Medicare GLP-1 Bridge or bill Medicare for these cash-pay options. Its current page says Medicare members may qualify for certain cash-pay treatments. That means no $50 Bridge price through Ro, no Part D claim, and no Medicare deductible or out-of-pocket credit. The Ro Body membership also sits on top of the medication price. But because the cash-pay prescription is not run through Medicare, it does not need Part D formulary approval. No Part D prior authorization. No Part D step therapy. No waiting for a new plan year. That is useful only after you have ruled out the cheaper Medicare paths above.

Ro's current FDA-approved cash options include Wegovy pill, Foundayo pill, Wegovy pen, and Zepbound KwikPen. The membership runs $39 for the first month, then $149/month, or as low as $74/month with the annual plan paid upfront. Medication costs extra.

→ See Ro's current FDA-approved cash-pay pricing and check availability in your state (affiliate link — we may earn a commission at no cost to you)

One more time, because it matters: if you might qualify for the $50 Bridge, stop and check that first. It is cheaper than the provider-stated cash prices above. Check your Bridge eligibility →

Why we don't link compounded GLP-1s here

Compounded semaglutide and tirzepatide are not FDA-approved drugs. FDA does not review them before marketing for safety, effectiveness, or quality. They are not generic versions of Wegovy or Zepbound, are not covered by the Bridge, and should not be described as equivalent to the approved brand-name products in this article.

We link compounded options on other pages where they genuinely fit. On a Medicare page — where a $50 FDA-approved option exists for some readers — recommending them before the Medicare paths would be doing you a disservice. So we don't.

What happens when the $50 Bridge ends?

Answer: The Medicare GLP-1 Bridge is scheduled to end December 31, 2027. CMS says the Part D portion of its planned BALANCE Model will not launch in 2027, and the agency has not announced a later Part D launch date. No permanent Medicare path for weight-loss-only GLP-1s has been established for 2028. Recheck CMS guidance and your 2028 plan materials during the 2027 enrollment season rather than assume the $50 arrangement continues.

What we know:

• The Bridge runs through December 31, 2027.
• BALANCE will not launch in Part D in 2027. CMS extended the Bridge while it gathers data ahead of a possible later Part D implementation.
• Your Bridge approval, once granted, is good through the end of 2027.

What nobody knows yet:

• Whether the Bridge gets extended again.
• Whether a different program replaces it.
• What 2028 plans will cover, or at what price.

Anyone writing confidently about 2028 Medicare GLP-1 coverage is speculating. We'll say plainly: we don't know, and we'll update this section when CMS does.

What to do about it: don't wait until your last refill. Talk to your prescriber about continuity in mid-2027, not December 2027. And read your 2028 Annual Notice of Change carefully when it arrives in September 2027.

If you're reading this on August 18, 2026, that's more than sixteen months of runway. It's a reason to start the process now, not a reason to wait for something better.

How we built this page, and what we actually verified

We're an independent site, and some links on this page earn us a commission. That's exactly why this section exists.

Who made it: The RX Index Research Team. No outside sponsor, no insurance company, and no Medicare plan reviewed or approved this page.

How we made it: We read CMS's Medicare GLP-1 Bridge materials for beneficiaries, pharmacies, prescribers, and Part D plan sponsors; CMS's negotiated-price documents for 2027; the 2027 Medicare Advantage and Part D Rate Announcement; Medicare.gov's plan-comparison and enrollment rules; the current FDA labels; the federal rules for enhanced Part D benefits and appeals; Humana's July 29, 2026 earnings transcript; and the live manufacturer and provider cash-pay terms quoted on this page. Then we matched each prescription purpose to the payer that actually decides it.

Provider-stated vs. independently verified — August 18, 2026

What we verified — August 18, 2026

• Bridge dates: July 1, 2026 through December 31, 2027
• Which plan types qualify by themselves, and which can qualify only with a standalone Part D plan
• Covered drugs and forms, including KwikPen-only for Zepbound and all current Wegovy forms
• The BMI and health criteria, measured at treatment start
• The cardiovascular overlap: past heart attack, stroke, or symptomatic PAD can support Bridge eligibility, but any major-cardiovascular-event-reduction purpose routes Wegovy to Part D
• The nine-drug 2026 lookback, and that CMS has not set the 2027 lookback period
• $50 copay, no Part D deductible, no TrOOP credit, and no Extra Help reduction
• Humana's role as central processor, not as a preferred plan
• The correct claim-routing order and the published help-desk numbers
• 2027 Part D figures: $700 standard deductible and $2,400 out-of-pocket threshold
• The January 1, 2027 negotiated semaglutide prices, package-price differences, and the limit of the formulary rule
• Current NovoCare and Ro cash-pay terms, labeled as provider-stated

What we did not verify

• Your county's plans. No national page can name the best plan for your address. Only Plan Finder, the plan documents, and a local counselor can.
• Any specific 2027 formulary or tier. As of August 18, 2026, final 2027 plan-specific comparisons were not yet available to shoppers. Check Plan Finder and the plan's own documents when 2027 data opens.
• Whether your doctors are in any plan's network. Check the plan's directory, then call the office.
• Whether a cash-pay prescription is medically appropriate for you. Only a licensed prescriber can decide that.

What we're not

We're not insurance agents. We don't sell Medicare plans and we don't get paid when you enroll in one. We're also not your doctor — nothing here is medical advice, and only your prescriber can decide whether a GLP-1 is right for you.

For personal, unbiased Medicare help, call your State Health Insurance Assistance Program (SHIP). It's free.

Update rule: We change the "Last verified" date only after a real factual review. We recheck this page weekly during Annual Enrollment and whenever CMS changes the Bridge, covered products, plan rules, or 2027 guidance.

Frequently asked questions

Is Humana the best Medicare Advantage plan because it processes the $50 program? No. CMS selected Humana as the national central processor for Bridge authorizations, claims, and pharmacy payments. That's an administrative contract. Being in a Humana plan doesn't make your Bridge request more likely to be approved.

Does every Medicare Advantage plan qualify for the GLP-1 Bridge? No. Medicare Advantage HMOs, HMO-POS plans, local and regional PPOs with drug coverage, Special Needs Plans, employer group Part D plans, LI NET, and standalone Part D plans qualify. PFFS, Cost, MSA, PACE, and other listed plan types do not qualify by themselves. A PFFS member can add a standalone Part D plan only when the PFFS plan does not already offer drug coverage. MSA and some Cost Plan members may also be able to add one. HMO, HMO-POS, and PPO members usually cannot do that without losing the Medicare Advantage plan.

Does Wegovy or Zepbound have to be on my plan's drug list for the $50 program? No. Bridge claims are processed outside your plan's normal payment system. Your formulary doesn't control a qualifying Bridge fill.

Does the Bridge cover Ozempic or Mounjaro? No. The Bridge covers Foundayo, Wegovy injection and tablets, and the Zepbound KwikPen. Ozempic and Mounjaro may be covered through regular Part D for type 2 diabetes, depending on your plan.

Does the Bridge cover every form of Zepbound? No. Only the KwikPen. Single-dose vials and single-dose pens are not covered. If your prescription says "Zepbound" without the form, ask your prescriber and pharmacist to confirm the exact product.

Does the $50 count toward my Part D out-of-pocket cap? No. Bridge spending sits outside Part D and doesn't move you toward the $2,100 cap in 2026 or the $2,400 cap in 2027.

Can Extra Help lower the $50 copay? No. Extra Help can reduce your costs for drugs paid through regular Part D, but it doesn't apply to the Bridge copay.

Can I use a manufacturer coupon with the Bridge? No. CMS says coupons and discount programs cannot be applied to Bridge claims. Manufacturer copay cards also generally exclude prescriptions paid through Medicare or other federal health programs. A separate cash/self-pay program is different because no Medicare claim is submitted.

Can I get a 90-day supply through the Bridge? No. One 28- or 30-day supply per fill.

Do I need my plan to deny it first? No. Your prescriber can send a potentially eligible prescription straight to the Bridge. But the pharmacy does need to submit the claim before the prior authorization, or you'll get a "patient not found" error.

How fast is the decision? The pharmacy usually sends the prior-authorization request to the prescriber within 24–72 hours after the Bridge claim. CMS says you and your prescriber should then be notified within 72 hours after the completed prior authorization is submitted.

I already lost weight. Does my lower BMI disqualify me? Not necessarily. CMS uses your BMI at the time you started GLP-1 treatment. Your prescriber can attest to that starting number.

Can a past heart attack or stroke qualify me for the Bridge? It can help. At a starting BMI of 27 or higher, a previous heart attack, previous stroke, or symptomatic peripheral artery disease is one way to meet the clinical criteria. But the prescription must be solely for weight management. If Wegovy is prescribed in any part to reduce major cardiovascular events, it goes to Part D.

Do I need new paperwork if I switch Bridge drugs? Yes. Your approval lasts through December 31, 2027 and covers refills and dose changes, but switching to a different covered Bridge drug requires a new prior authorization.

Which Medicare Advantage plan covers Zepbound for sleep apnea? There's no national answer. Sleep apnea prescriptions go through regular Part D, so you have to compare the specific plans in your ZIP code — formulary status, tier, prior authorization, and exception rules.

When can I switch Medicare Advantage plans? Annual Enrollment runs October 15 to December 7, 2026 for coverage starting January 1, 2027. If you're already in a Medicare Advantage plan, you get one more switch between January 1 and March 31, 2027. Certain life events create Special Enrollment Periods.

Will Ozempic and Wegovy get cheaper on Medicare in 2027? The underlying negotiated price drops for Part D-covered uses. The $274 number is a standardized 30-day price; actual package prices vary, and it is not your copay. What you pay still depends on your plan and benefit stage.

Does the $274 semaglutide price make weight-loss-only Wegovy a Part D benefit? No. The negotiated-price rule does not remove the basic Part D exclusion for a drug used only for weight loss. Eligible weight-management prescriptions still use the Bridge.

My doctor says Medicare never covers GLP-1s for weight loss. Is that right? Not anymore. Basic Part D still excludes a GLP-1 used only for weight loss, but the Medicare GLP-1 Bridge has operated outside Part D since July 1, 2026 for qualifying beneficiaries and covered products.

The bottom line

If your GLP-1 is prescribed solely for weight management and you qualify for the Bridge, stop shopping for a carrier. Confirm your plan type qualifies, confirm the clinical criteria, and get the prescription sent to the pharmacy in the right order. Your carrier barely matters.

If your GLP-1 is for type 2 diabetes, moderate-to-severe sleep apnea, qualifying MASH, or Wegovy prescribed to reduce major cardiovascular events, your exact plan matters more than almost any other decision you'll make this fall. Compare specific local plans by the exact drug and form, check your doctors, check every other prescription, and compare total annual cost.

And if you're being forced to shop because your plan is ending — you're not behind. Your Annual Notice of Change arrives in September. 2027 plan comparison information opens October 1. You have time to do this right.

Still not sure which GLP-1 path is right for you? Use our free tool. It takes about two minutes.

→ Find My GLP-1 Path

Sources

• CMS — Medicare GLP-1 Bridge overview
• CMS — Medicare GLP-1 Bridge information for providers
• CMS — Medicare GLP-1 Bridge information for pharmacies
• CMS — Medicare GLP-1 Bridge information for Part D plans
• Medicare.gov — Compare Medicare Advantage plan types
• Medicare.gov — When you can buy Medigap and guaranteed-issue rights
• Medicare.gov — Medicare Plan Finder
• CMS — CY 2027 Medicare Advantage and Part D Rate Announcement
• CMS — Selected drugs and negotiated prices
• CMS — BALANCE Model
• FDA — current Wegovy prescribing information
• FDA — current Foundayo prescribing information
• FDA — Zepbound approval for obstructive sleep apnea
• FDA — Understanding the risks of compounded drugs
• eCFR — Part D benefits and supplemental drug coverage
• eCFR — Part D coverage determinations and appeals
• eCFR — Medicare Advantage rebates for supplemental benefits
• Humana — July 29, 2026 earnings-call transcript
• NovoCare Pharmacy — Wegovy cash/self-pay terms
• Ro — insurance and government-plan eligibility
• Ro — current membership and medication pricing
• r/medicare GLP-1 Bridge discussion — reader language only, not coverage evidence

Last verified: August 18, 2026. We recheck this page weekly during Annual Enrollment.